The role of dipeptidylpeptidase-4 inhibitors in the current therapy of type 2 diabetes mellitus.

Prof. L.V. Zhuravlyova, M.V. Filonenko.

Kharkiv National Medical University.

Recent advances in the study of the pathogenesis of type 2 diabetes, including the mechanisms of regulation of postprandial blood glucose level, have led to the emergence of new treatment strategies aimed at overcoming dysfunction of the Langerhans islands, including those that affect the incretine hormones of the intestines. Dipeptidylpeptidase-4 inhibitors are a relatively new class of oral hypoglycemic drugs. The inhibition of the destruction of the incretin hormone — glucagon-like peptide-1 — has a positive effect on glucose metabolism, which includes both potentiation of glucose-induced increase of insulin level and inhibition of glucagon secretion. An absence of significant side effects and lack of influence on bodyweight, low risk of hypoglycemia positively distinguish the class of dipeptidyl peptidase-4 inhibitors from other groups of oral hypoglycemic drugs.

Key Words: type 2 diabetesmellitus, dipeptidylpeptidase-4 inhibitors, vildagliptin.

https://dx.doi.org/10.15407/internalmed2020.02.080

Download.PDF

For citing:

1. Журавльова, Л.В. Роль інгібіторів дипептиділпептидази-4 в сучасній терапії цукрового діабету 2 типу /Л.В. Журавльова, М.В. Філоненко // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2020. – № 2. – С. 80-84. doi: 10.15407/internalmed2020.02.080.
2. Zhuravlyova LV, Filonenko MV. [The role of dipeptidylpeptidase-4 inhibitors in the current therapy of type 2 diabetes mellitus]. Shidnoevr. z. vnutr. simejnoi med. 2020;2:80-84. Ukrainian. doi: 10.15407/internalmed2020.02.080.

References:

  1. Dem’janenko V. Vozmozhnosti ingibitorov DPP-4 v sovremennoj terapii saharnogo diabeta 2-go tipa: rekomendacii specialistov. International journal of endocrinology. 2011;3 (35):18-22. Russian
  2. Skvorcov VV, Tumarenko AV. Sovremennye aspekty farmakoterapii saharnogo diabeta 2 tipa – fokus na ingibitory DPP-4. Kachestvennaja klinicheskaja praktika. 2012;1:28-34. Russian
  3. Ahren B., Schweizer A., Dejager S. et al.Mechanisms of action of the dipeptidyl peptidase- inhibitor 4 vildagliptininin humans // Diabetes, Obesity and Metabolism. – 2011. – Vol.13 (9). – P. 775-783. doi: 10.1111/j.1463-1326.2011.01414.x
  4. Croxtall J, Keam S. Vildagliptin. Drugs. 2008;68(16):2387-2409. http://dx.doi.org/10.2165/0003495-200868160-00009
  5. Davies MJ, D’Alessio DA, Fradkin J. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(1): S1-S2. https://doi.org/10.2337/dci18-0033
  6. Davis T. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity and Metabolism. 2014;16(10):891-899. http://dx.doi.org/10.1111/dom.12295
  7. Deacon C, Holst J. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy. 2013;14(15):2047-2058. http://dx.doi.org/10.1517/14656566.2013.824966
  8. Deacon C, Lebovitz H. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism. 2016;18(4):333-347. http://dx.doi.org/10.1111/dom.12610
  9. Dejager S, Razac S, Foley J, Schweizer A. Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study. Hormone and Metabolic Research. 2007;39(3):218-223. http://dx.doi.org/10.1055/s-2007-970422
  10. Esposito K, Chiodini P, Maiorino M, Capuano A, Cozzolino D, Petrizzo M, Bellastella G, Giugliano D. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892-e005892. http://dx.doi.org/10.1136/bmjopen-2014-005892
  11. Fonseca V, Schweizer A, Albrecht D, Baron M, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155. http://dx.doi.org/10.1007/s00125-007-0633-0
  12. Gallwitz B. Clinical Use of DPP-4 Inhibitors. Frontiers in Endocrinology. 2019;10:389-395. http://dx.doi.org/10.3389/fendo.2019.00389
  13. Gallwitz B. Novel therapeutic approaches in diabetes. Endocrine Development. 2016;31:43-56. doi:10.1159/000439372.
  14. Green J, Bethel M, Paul S, Ring A, Kaufman K, Shapiro D, Califf R, Holman R. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal. 2013;166(6):983-997. http://dx.doi.org/10.1016/j.ahj.2013.09.003
  15. Schweizer A. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vascular Health and Risk Management. 2008;4:481-492. http://dx.doi.org/10.2147/vhrm.s2503
  16. The International Diabetes Federation (IDF). Canadian Journal of Diabetes. 2008;32(4):379. http://dx.doi.org/10.1016/s1499-2671(08)24263-2
  17. Monami M, Vitale V, Ambrosio M, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E. Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy. 2012;29(9):736-746. http://dx.doi.org/10.1007/s12325-012-0045-5
  18. Mosenzon O, Raz I, Scirica B, Hirshberg B, Stahre C, Steg P, Davidson J, Ohman P, Price D, Frederich B, Udell J, Braunwald E, Bhatt D. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes/Metabolism Research and Reviews. 2013;29(5):417-426. http://dx.doi.org/10.1002/dmrr.2413
  19. Nauck M, Meier J, Cavender M, Abd El Aziz M, Drucker D. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849-870. http://dx.doi.org/10.1161/circulationaha.117.028136
  20. Rosenstock J, Perkovic V, Alexander J, Cooper M, Marx N, Pencina M, Toto R, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl U, Woerle H, George J, von Eynatten M, McGuire D. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular Diabetology. 2018;17(1):. http://dx.doi.org/10.1186/s12933-018-0682-3
  21. Scheen A. The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety. 2018;17(4):387-405. http://dx.doi.org/10.1080/14740338.2018.1444027
  22. Sesti G, Avogaro A, Belcastro S, Bonora B, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C, Orsi E, Picconi F, Resi V, Bonora E, Purrello F. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica. 2019;56(6):605-617. http://dx.doi.org/10.1007/s00592-018-1271-3
  23. Tatosian D, Guo Y, Schaeffer A, Gaibu N, Popa S, Stoch A, Langdon R, Kauh E. Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin. Diabetes Therapy. 2013;4(2):431-442. http://dx.doi.org/10.1007/s13300-013-0045-8
  24. White W, Bakris G, Bergenstal R, Cannon C, Cushman W, Fleck P, Heller S, Mehta C, Nissen S, Perez A, Wilson C, Zannad F. EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). American Heart Journal. 2011;162(4):620-626.e1. http://dx.doi.org/10.1016/j.ahj.2011.08.004